TuHURA Biosciences, Inc. Common Stock (HURA) Stock
Key stats
- Market cap
- $96.86M
- Price / Earnings ratio
- -3.1x
- EPS (TTM)
- -$0.54
- Volume
- Loading
- 52-week high
- $3.43
- 52-week low
- $0.41
Source: third-party data provider, as of November 13, 2026
Compare with HURA
Recent news
TuHURA Reports Early Responses in Deep-Seated Merkel Cell Cancer Study
TuHURA Reports Early Responses in Deep-Seated Merkel Cell Cancer Study
HURA
TuHURA Biosciences Highlights Phase III IFx Push, AML Trial Plans at Canaccord
TuHURA Biosciences Highlights Phase III IFx Push, AML Trial Plans at Canaccord
HURA
This Small-Cap Biotech Stock Has Sparked A 7,000% Surge In Retail Chatter — Here’s Why
This Small-Cap Biotech Stock Has Sparked A 7,000% Surge In Retail Chatter — Here’s Why
HURANews tone: automated (AI) classification of the article's content, not a price prediction.
Technical indicators
- RSI 14
- 35.89
- MACD 12/26/9
- -0.11
- EMA 9 of MACD
- -0.07
- MACD histogram
- -0.04
- SMA 50
- $1.95
- Price below SMA 50
- EMA 50
- $1.92
- Price below EMA 50
- SMA 200
- $2.01
- Price below SMA 200
- EMA 200
- $1.86
- Price below EMA 200
Calculated by Gotrade from daily closing prices, as of November 11, 2026. Technical data, not a recommendation.
Analyst ratings
Analyst consensus: Buy
Based on 2 analyst ratings
Third-party analyst opinion, not a recommendation from Gotrade.
Financials
Performance
Debt & Balance Sheet
Revenue to Profit
2025Earnings
No data available
Source: third-party data provider
Latest news
TuHURA Reports Early Responses in Deep-Seated Merkel Cell Cancer Study
TuHURA Reports Early Responses in Deep-Seated Merkel Cell Cancer Study
HURATuHURA Biosciences Highlights Phase III IFx Push, AML Trial Plans at Canaccord
TuHURA Biosciences Highlights Phase III IFx Push, AML Trial Plans at Canaccord
HURAThis Small-Cap Biotech Stock Has Sparked A 7,000% Surge In Retail Chatter — Here’s Why
This Small-Cap Biotech Stock Has Sparked A 7,000% Surge In Retail Chatter — Here’s Why
HURANews tone: automated (AI) classification of the article's content, not a price prediction.
About TuHURA Biosciences, Inc. Common Stock
TuHURA Biosciences Inc is a Phase 3 registration stage immuno-oncology company developing novel technologies to overcome resistance to cancer immunotherapy. The company's personalized cancer vaccine candidate, IFx-2.0, is designed to overcome primary resistance to checkpoint inhibitors. It is preparing to initiate a single randomized placebo-controlled Phase 3 registration trial of IFx-2.0 administered as an adjunctive therapy to Keytruda (pembrolizumab) in first-line treatment for advanced or metastatic Merkel Cell Carcinoma.
Key Executives
| Name | Title | Year Born |
|---|---|---|
| Dr. James A. Bianco M.D. | President, CEO & Director | 1957 |
| Mr. Dan Dearborn CPA | Executive VP of Finance & CFO | 1967 |
| Mr. Michael Lawman | Co-Founder | — |
| Ms. Patricia Lawman | Co-Founder | — |
| Mr. Michael Krsulich | Head of Quality Assurance | — |
| Ms. Amanda Garofalo | Senior Vice President of Clinical Operations | — |
Fundamentals
Valuation
Profitability
Trading
Source: third-party data provider, as of November 13, 2026
Technical indicators
- RSI 14
- 35.89
- MACD 12/26/9
- -0.11
- EMA 9 of MACD
- -0.07
- MACD histogram
- -0.04
- SMA 50
- $1.95
- Price below SMA 50
- EMA 50
- $1.92
- Price below EMA 50
- SMA 200
- $2.01
- Price below SMA 200
- EMA 200
- $1.86
- Price below EMA 200
Calculated by Gotrade from daily closing prices, as of November 11, 2026. Technical data, not a recommendation.
Analyst views
2 analyst ratings
Third-party analyst opinion, not a recommendation from Gotrade.
- Low
- $9.00
- Average
- $9.50
- High
- $10.00
Seasonality
Monthly price change (%)| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | -10.5 | +38.3 | -3.0 | +4.5 | -11.4 | -0.5 | +3.4 | -2.5 | -11.6 |
